PharmaFocus Today – Page 112 – media

Repertoire and Bristol Myers Squibb link on autoimmune disease vaccines

Repertoire Immune Medicines has collaborated with Bristol Myers Squibb to develop tolerising vaccines for autoimmune diseases. The partnership will leverage Repertoire’s DECODE platform to map the immune synapse and create targeted treatments with the expertise of Bristol Myers Squibb in developing and commercialising new immune medicines. It will develop selective, efficacious and durable treatments for patients with autoimmune diseases by resetting the immune system. Repertoire will receive $65m upfront and could earn $1.8bn in additional payments, including development, regulatory and commercial milestones and tiered royalties. The company will utilise its DECODE T cell receptor (TCR)-epitope discovery platform and lipid nanoparticle delivery technology to develop the tolerising vaccine development candidates. The platform will also be used during clinical development to monitor immune responses to the tolerising vaccines in patients to provide insights into the vaccines’ pharmacodynamic effect. Repertoire CEO Torben Straight Nissen stated: “This agreement ...
- Source: https://www.pharmaceutical-technology.com/news/repertoire-bristol-vaccines/?cf-view
- 70
- May 2, 2024
Technoderma Medicines Advances TDM-180935 Atopic Dermatitis Clinical Program with Phase 2 Trial

CHENGDU, China, April 29, 2024 /PRNewswire/ — Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing patients in its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ointment. This clinical trial in the Atopic Dermatitis (AD) program includes 8 weeks dosing of two different active formulation strengths and placebo in a study entitled, “A Randomized, Vehicle-Controlled, Parallel Group Study of Topical TDM-180935 to Evaluate the Preliminary Efficacy, Safety, Tolerability, and Pharmacokinetics in Atopic Dermatitis Patients”. It is a randomized, vehicle-controlled, parallel group comparison study with an open-label PK sub-study. Objectives are to evaluate the safety and efficacy of topical TDM-180935 as well aspharmacokinetics. Seven U.S. clinical sites are currently participating in this study under an open IND with FDA. Arthur P. Bertolino, MD, PhD, MBA, Chief Medical Officer at Technoderma Medicines commented, “We expect the current study to support ...
- Source: https://en.prnasia.com/releases/global/technoderma-medicines-advances-tdm-180935-atopic-dermatitis-clinical-program-with-phase-2-trial-445242.shtml
- 76
- May 2, 2024
Degu Insulin Liraglutide Injection was approved for clinical application

Tonghua Dongbao Pharmaceutical Co., Ltd (hereinafter referred to as “Tonghua Dongbao”) has recently obtained the clinical trial approval notification of Degu Insulin Liraglutide Injection issued by the Center for Drug Evaluation (CDE) of the State Drug Administration. The clinical approval of Degu Insulin Liraglutide Injection is another significant progress in the research and development of insulin analog GLP-1RA compound preparation, which will further enhance the company’s competitiveness in the field of endocrine therapy. In the future, the Company is expected to accelerate the process of clinical trials and speed up the approval and listing of its products by virtue of its R&D advantages accumulated in the field of diabetes treatment over the years, so as to provide richer and better choices for clinical medication. Degu Insulin Liraglutide Injection has a broad market prospect in the future, and the market scale shows a rapid growth trend. Its original Degu Insulin Liraglutide ...
- Source: drugdu
- 81
- May 1, 2024
FDA Approves Pfizer’s Beqvez for the Treatment of Adults with Moderate to Severe Hemophilia B

Don Tracy, Associate Editor Beqvez, a one-time gene therapy, offers hope to patients with moderate to severe hemophilia B who use regular factor IX prophylaxis, suffer severe hemorrhages, or recurrent serious bleeding.Pfizer announced that the FDA has approved Beqvez (fidanacogene elaparvovec-dzkt) as a one-time gene therapy for adults with moderate to severe hemophilia B. The therapy is indicated for patients who currently use factor IX (FIX) prophylaxis therapy, have a history of severe hemorrhage, or experience frequent serious bleeding with no neutralizing antibodies to the adeno-associated virus serotype. In clinical trials, Beqvez was found to help patients to produce their own FIX, lowering the need for regular intravenous (IV) infusions. The approval was based on promising data from the Phase III open-label, single-arm BENEGENE-2 trial, which evaluated the efficacy and safety of Beqvez in 45 males aged 18 to 65 years with moderately severe to severe hemophilia B. All participants ...
- Source: drugdu
- 83
- May 1, 2024
A Flawed Measure of Health

It’s time we move beyond BMI and adopt a holistic approach to truly gauge health. By Gretchen Zimmermann Body Mass Index (BMI) has long been regarded as a standard measure for assessing weight-related health risks and, more recently, determining eligibility for anti-obesity medications like GLP-1 receptor agonists semaglutide (Wegovy) and tirzepatide (Zepbound), according to the FDA. BMI, calculated from weight and height, offers a simplistic yet flawed assessment of health. It was initially designed for non-Hispanic white populations and overlooks nuances like muscle mass, fat distribution, and ethnic background, which can influence certain risk factors. It’s an antiquated measure that perpetuates inequities in healthcare and misses the mark for calculating cardiometabolic conditions. The perception that a “normal” BMI is ideal and an “overweight to obese” BMI is not ideal only exacerbates bias within the medical community and complicates our efforts to solve the obesity crisis. Individuals with an overweight to ...
- Source: drugdu
- 82
- May 1, 2024
First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable unit could revolutionize the way samples are collected for diagnostic tests. ReadyGo Diagnostics’ (Bath, UK) Sampler device incorporates both the swab and collection buffers into one device, making it exceptionally user-friendly. It is the world’s first universal tool of its kind that ensures convenience, reliability, and reproducibility right from the initial step of a diagnostic test. The patented technology behind the ReadyGo Sampler uses specially engineered materials that not only allow the device to collect the exact amount of sample required instantly but also rapidly break open viruses and bacteria, making them readily detectable in specific tests. The ReadyGo Sampler device is intended to be a more user-oriented alternative to conventional swab-based sample collection methods by combining sample collection and processing into one ...
- Source: drugdu
- 80
- May 1, 2024
Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays

Osteoarthritis (OA) is the most prevalent form of arthritis, impacting millions worldwide and resulting in significant economic and social costs. Although no cure exists currently, the effectiveness of emerging therapies might depend on early detection and slowing the disease’s progression before severe debilitation occurs. Traditional diagnostic methods typically do not catch the disease until it has already caused structural damage to the joint. For example, an abnormal X-ray can reveal definitive signs of knee OA, but by the time these signs are visible, the disease has often been advancing for years. Now, a novel blood test has been developed that can predict the onset of knee OA at least eight years before its signs become visible on X-rays. Researchers at Duke Health (Durham, NC, USA) validated the accuracy of the blood test, which detects key biomarkers of OA. Their findings indicate that the test not only predicts the onset of ...
- Source: drugdu
- 115
- May 1, 2024
ETH Zurich researchers use AI to develop drug molecules based on protein structures

Researchers from ETH Zurich have developed a new generative artificial intelligence (AI)-based computer process to develop drug molecules based on a protein’s three-dimensional surface. The new process could revolutionise drug research, making it possible to generate active pharmaceutical ingredients quickly and easily. The new computer process’ algorithm was developed in collaboration with ETH’s professor Gisbert Schneider and former doctoral student Kenneth Atz, using AI to design new active pharmaceutical ingredients. Researchers trained the AI model with information from hundreds of thousands of known interactions between chemical molecules and the corresponding three-dimensional protein structures. The algorithm generates the blueprints for potential drug molecules that can increase or inhibit the activity of proteins with a known three-dimensional shape. The generative AI then designs molecules that bind specifically to the protein according to the lock-and-key principle to be interacted with. “This means that when designing a drug molecule, we can be sure that ...
- Source: drugdu
- 81
- May 1, 2024
KCL study reveals particles in cows’ milk effective for oral delivery of RNA drugs

In a new study, researchers from King’s College London (KCL) have revealed that tiny particles present in cows’ milk could offer a new and effective method for the oral delivery of ribonucleic acid (RNA) drugs. Published in the Journal of Nanobiotechnology, the tiny particles known as extracellular vesicles (EV) could help protect and deliver RNA drugs following oral administration. RNA therapies are a powerful class of drugs based on nucleic acids that offer a way to target previously untreatable diseases on a molecular level. Despite successful administration via injection, there has been no successful way to deliver them orally, as the drugs are destroyed by the harsh conditions of the gut. Researchers extracted EVs from cows’ milk and loaded them with RNA molecules to treat inflammatory bowel disease (IBD). EVs are nanoscale transporters that carry biological molecules in a protective coat throughout the body, controlling and regulating the access of ...
- Source: drugdu
- 104
- May 1, 2024
Study reveals high levels of antibiotic resistance in meat sold for consumption

New research presented at the ESCMID Global Congress (formerly ECCMID) in Barcelona, Spain (27-30 April) has found substantial levels of resistance to critically important antibiotics in meat sold for human and animal consumption. The study is by Dr Jordan Sealey, Professor Matthew Avison and colleagues from the University of Bristol, UK. Meat sold for consumption by humans and companion animals in the UK is regulated by the UK Government Food Standards Agency (FSA) to ensure it falls within bacterial limits deemed safe. However, while meat is tested for the types and amounts of pathogens present, it is not tested for resistant opportunistic pathogens (e.g. Escherichia coli). Multiple studies have shown a strong association between feeding dogs a diet of uncooked meat (raw dog food) and an increased risk of excreting E. coli resistant to critically important antibiotics in their faeces. It is possible that pet animals eating raw meat increases ...
- Source: drugdu
- 95
- April 30, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.